IP Library Granted Patent US 8,987,203
Granted Patent B2
US 8,987,203 · App. 12/515,202 · Granted Mar 24, 2015

Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein

Inventors: Johannes Petrus Thomas Maria Van Leeuwen (Amstelveen, NL); Hermanus Johannes Marco Eijken (Rotterdam, NL)
Assignee: Arcarios B.V.
C12N5/0654A61K38/17C12N2501/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,987,203
App. No.
12/515,202
Granted
Mar 24, 2015
Kind
B2
Abstract

The present invention relates to methods for selecting a candidate therapeutic agent for controlling mineralization of an extracellular matrix in a tissue of a subject. The invention further relates to a cell culture mineralization model comprising a culture of an extracellular matrix producing cell under conditions that support extracellular matrix formation and matrix maturation, a test compound, and means and methods for determining in expression levels of genes encoding matrix proteins.

Claims (7)

1. A method of stimulating mineralization in an extracellular matrix by an osteoblast in a human subject comprising:

administering to said subject an effective amount of an activin-A inhibitor protein that is not follistatin, or a pharmaceutical composition thereof, wherein the activin-A inhibitor protein prevents an interaction between activin-A and an activin receptor on an osteoblast, and wherein the osteoblast mineralizes the extracellular matrix.

2. The method of claim 1 wherein the activin receptor is a type-II activin receptor.

3. The method of claim 1 wherein said administering is by intravenous, intraperitoneal or intracapsular administration.

4. The method of claim 1 wherein said administering is by means of a pump or sustained release form.

5. The method of claim 1 wherein said administering results in local concentration of said activin-A inhibitor protein of about 50-500 ng/ml.

6. The method of claim 1 wherein said activin-A inhibitor protein is conjugated to a targeting agent.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2018
From: ARCARIOS B.V.
To: ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM
Reel/Frame 044584/0679 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S ADDRESS. IT SHOULD BE RECORDED AS: DR. MOLEWATERPLEIN 40, ROTTERDAM, NETHERLANDS 3015 GD PREVIOUSLY RECORDED ON REEL 025838 FRAME 0895. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNEE'S PREVIOUS ADDRESS WAS: DR. MOLEWATERPLEIN 50, ROTTERDAM,NETHERLANDS 3015 GE. Recorded Mar 2, 2012
From: ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM
To: ARCARIOS BV
Reel/Frame 027795/0291 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2011
From: ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM
To: ARCARIOS BV
Reel/Frame 025838/0895 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2010
From: VAN LEEUWEN, JOHANNES PETRUS THOMAS MARIA; EIJKEN, HERMANUS JOHANNES MARCO
To: ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM
Reel/Frame 023880/0107 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2009
From: VANLEEUWEN, JOHANNES PETRUS THOMAS MARIA; EIJKEN, HERMANUS JOHANNES MARCO
To: ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM
Reel/Frame 023228/0738 →
Priority Claims (1)
WO PCT/NL2006/000576 · Nov 17, 2006 · international
Continuity (1)
Related Publication 20100113327A1 · May 6, 2010